New FDA-Cleared Software Update Enhances MRI Analysis for ARIA Detection

NeuroQuant v5.0 (Cortechs.ai, San Diego, CA), the latest update to NeuroQuant (Cortechs.ai, San Diego, CA) neuroimaging analysis software, has received Food and Drug Administration (FDA) 510(k) clearance. The update enables the identification and evaluation of focal brain lesions in MRI images, which are associated with traumatic brain injury (TBI) and cerebral amyloid deposition diseases such as cerebral amyloid angiopathy (CAA) and Alzheimer disease (AD).

According to a statement from Cortechs.ai, the 5.0 update will advance the capabilities of NeuroQuant when employed by radiologists for segmentation of amyloid-related imaging abnormalities (ARIA) in people who are undergoing treatment for AD using anti-amyloid therapies. Segmentation is the process by which a medical image is partitioned into multiple segments enabling the quantification of tissue volumes or detection of abnormalities such as tumors or lesions. NeuroQuant performs volumetric and segmentation analysis using artificial intelligence (AI) software and is intended to assist in monitoring, visualizing, and measuring abnormalities such as ventricle expansion, tissue atrophy, and swelling, synthesizing patient data into detailed, clinically focused reports.

Nate White, PhD, Chief Technology Officer of Cortechs.ai, stated “This software equips clinicians with cutting-edge tools to better detect and quantify brain lesions with greater accuracy and precision, aiding in the management of complex conditions such as TBI and Alzheimer’s.”